GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » Retained Earnings

Enzychem Lifesciences (XKRX:183490) Retained Earnings : ₩19,530 Mil (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Enzychem Lifesciences's retained earnings for the quarter that ended in Dec. 2024 was ₩19,530 Mil.

Enzychem Lifesciences's quarterly retained earnings declined from Jun. 2024 (₩37,461 Mil) to Sep. 2024 (₩35,885 Mil) and declined from Sep. 2024 (₩35,885 Mil) to Dec. 2024 (₩19,530 Mil).

Enzychem Lifesciences's annual retained earnings increased from Dec. 2022 (₩-151,053 Mil) to Dec. 2023 (₩41,910 Mil) but then declined from Dec. 2023 (₩41,910 Mil) to Dec. 2024 (₩19,530 Mil).


Enzychem Lifesciences Retained Earnings Historical Data

The historical data trend for Enzychem Lifesciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences Retained Earnings Chart

Enzychem Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -95,176.35 -124,664.90 -151,053.25 41,910.07 19,529.59

Enzychem Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41,910.07 40,821.38 37,461.18 35,884.94 19,529.59

Enzychem Lifesciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Enzychem Lifesciences  (XKRX:183490) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Enzychem Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences Headlines

No Headlines